KR102488927B1 - 벤조산리튬의 공-결정 및 그의 용도 - Google Patents

벤조산리튬의 공-결정 및 그의 용도 Download PDF

Info

Publication number
KR102488927B1
KR102488927B1 KR1020217037292A KR20217037292A KR102488927B1 KR 102488927 B1 KR102488927 B1 KR 102488927B1 KR 1020217037292 A KR1020217037292 A KR 1020217037292A KR 20217037292 A KR20217037292 A KR 20217037292A KR 102488927 B1 KR102488927 B1 KR 102488927B1
Authority
KR
South Korea
Prior art keywords
alkyl
crystal
disorder
certain embodiments
former
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020217037292A
Other languages
English (en)
Korean (ko)
Other versions
KR20210142769A (ko
Inventor
귀추안 에밀 차이
칭-쳉 왕
티엔-란 시에
유안-천 로
Original Assignee
신유알엑스 인터내셔널 (타이완) 코포레이션
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 신유알엑스 인터내셔널 (타이완) 코포레이션 filed Critical 신유알엑스 인터내셔널 (타이완) 코포레이션
Publication of KR20210142769A publication Critical patent/KR20210142769A/ko
Application granted granted Critical
Publication of KR102488927B1 publication Critical patent/KR102488927B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/14—Alkali metal chlorides; Alkaline earth metal chlorides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
    • C07C215/46—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C07C215/48—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by hydroxy groups
    • C07C215/54—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by hydroxy groups linked by carbon chains having at least three carbon atoms between the amino groups and the six-membered aromatic ring or the condensed ring system containing that ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/02—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms with only carbon-to-carbon double bonds as unsaturation
    • C07C57/03—Monocarboxylic acids
    • C07C57/10—Sorbic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/30—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing six-membered aromatic rings
    • C07C57/42—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing six-membered aromatic rings having unsaturation outside the rings
    • C07C57/44—Cinnamic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C63/00—Compounds having carboxyl groups bound to a carbon atoms of six-membered aromatic rings
    • C07C63/04—Monocyclic monocarboxylic acids
    • C07C63/06—Benzoic acid
    • C07C63/08—Salts thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/79—Acids; Esters
    • C07D213/80—Acids; Esters in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Inorganic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyridine Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
KR1020217037292A 2016-06-13 2017-06-13 벤조산리튬의 공-결정 및 그의 용도 Active KR102488927B1 (ko)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201662349582P 2016-06-13 2016-06-13
US62/349,582 2016-06-13
KR1020197000865A KR102338171B1 (ko) 2016-06-13 2017-06-13 벤조산리튬의 공-결정 및 그의 용도
PCT/CN2017/088044 WO2017215592A1 (en) 2016-06-13 2017-06-13 Co-crystals of lithium benzoate and uses thereof

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020197000865A Division KR102338171B1 (ko) 2016-06-13 2017-06-13 벤조산리튬의 공-결정 및 그의 용도

Publications (2)

Publication Number Publication Date
KR20210142769A KR20210142769A (ko) 2021-11-25
KR102488927B1 true KR102488927B1 (ko) 2023-01-13

Family

ID=60663075

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020217037292A Active KR102488927B1 (ko) 2016-06-13 2017-06-13 벤조산리튬의 공-결정 및 그의 용도
KR1020197000865A Active KR102338171B1 (ko) 2016-06-13 2017-06-13 벤조산리튬의 공-결정 및 그의 용도

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020197000865A Active KR102338171B1 (ko) 2016-06-13 2017-06-13 벤조산리튬의 공-결정 및 그의 용도

Country Status (11)

Country Link
US (2) US10815184B2 (https=)
EP (1) EP3468946A4 (https=)
JP (1) JP6958923B2 (https=)
KR (2) KR102488927B1 (https=)
CN (1) CN109563024B (https=)
CA (1) CA3027300C (https=)
IL (1) IL263486B (https=)
MX (1) MX2018015463A (https=)
RU (2) RU2765625C2 (https=)
TW (1) TWI736635B (https=)
WO (1) WO2017215592A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2936094T3 (es) * 2016-06-13 2023-03-14 Syneurx Int Taiwan Corp Cocristales de benzoato de sodio y usos de los mismos
WO2021245697A1 (en) 2020-06-01 2021-12-09 Celagenex Research (India) Pvt. Ltd. Novel synergistic medicinal compositions for treating dysfunctional d-serine signaling

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3498989A (en) 1969-04-16 1970-03-03 American Home Prod Certain 8-substituted-2-alkyl-3-benzoyl esters of ecgonine and derivatives thereof
US3870715A (en) 1972-03-09 1975-03-11 Nikolaus R Hansl Substituted amino ethyl meta benzoic acid esters
US4041174A (en) 1974-08-16 1977-08-09 Rom-Amer Pharmaceuticals, Ltd. Method of treating depression
US5204356A (en) 1985-07-24 1993-04-20 Glaxo Group Limited Treatment of anxiety
US6150354A (en) 1987-01-15 2000-11-21 Bonnie Davis Compounds for the treatment of Alzheimer's disease
GB8819494D0 (en) 1988-08-16 1988-09-21 Ucb Sa Use of 2-amino-4-morpholino-6-propyl-1 3 5-triazines for preparation of psychotropic medicaments
US6746678B1 (en) 1991-02-22 2004-06-08 Howard K. Shapiro Method of treating neurological diseases and etiologically related symptomology using carbonyl trapping agents in combination with medicaments
ATE231723T1 (de) 1991-02-22 2003-02-15 Howard K Shapiro Verwendung von pharmazeutischen wirkstoffen zur behandlung von krankheitssymptomen neurologischer erkrankungen und etiologisch verwandter symptomenkomplexe
FR2700117B1 (fr) 1993-01-07 1995-02-03 Rhone Poulenc Rorer Sa Application d'anticonvulsivants dans le traitement de la maladie de Parkinson et des syndromes parkinsoniens.
DE4340273A1 (de) 1993-11-26 1995-06-01 Karla Dr Lehmann Arzneimittel zur Prophylaxe des Morbus Alzheimer und zur Verhütung des Fortschreitens dieser Erkrankung
US5453425A (en) 1994-07-11 1995-09-26 Janssen Pharmaceutica N.V. Risperidone oral formulation
WO2001041707A2 (en) 1999-12-08 2001-06-14 Vanderbilt University Modulation of in vivo glutamine and glycine levels in the treatment of autism
KR100818875B1 (ko) 2000-08-14 2008-04-01 테바 파마슈티컬 인더스트리즈 리미티드 리스페리돈의 제조
EP1412515A2 (en) 2001-01-16 2004-04-28 Genset Treatment of cns disorders using d-amino acid oxidase and d-aspartate oxidase antagonists
US20030185754A1 (en) 2001-01-16 2003-10-02 Genset, S.A. Treatment of CNS disorders using D-amino acid oxidase and D-aspartate oxidase antagonists
US7927613B2 (en) 2002-02-15 2011-04-19 University Of South Florida Pharmaceutical co-crystal compositions
US20070053976A1 (en) 2002-05-17 2007-03-08 Eisai R & D Management Co., Ltd. Novel combination of drugs as antidepressant
US7053122B2 (en) 2002-08-09 2006-05-30 Pfizer Inc Therapeutic use of aryl amino acid derivatives
US7273889B2 (en) 2002-09-25 2007-09-25 Innovative Drug Delivery Systems, Inc. NMDA receptor antagonist formulation with reduced neurotoxicity
KR100777904B1 (ko) 2002-10-24 2007-11-28 메르츠 파마 게엠베하 운트 코. 카가아 1-아미노시클로헥산 유도체 및 아세틸콜린에스테라제 저해제를 포함하는 약학적 제품 및 이를 이용한 복합 치료
WO2004065348A1 (en) 2003-01-23 2004-08-05 Pfizer Products Inc. Pharmaceutically acceptable salts of sertraline and pharmaceutical compositions thereof
EP1628660A4 (en) 2003-06-02 2010-06-02 Samaritan Pharmaceuticals Inc METHOD AND COMPOSITIONS FOR MODULATING THE CORTISOL SERUM MIRRORS
CN102010382A (zh) 2003-12-29 2011-04-13 塞普拉科公司 苯并[d]异噁唑-3-醇DAAO抑制剂
ATE504588T1 (de) 2004-01-27 2011-04-15 Synthon Bv Stabile salze von olanzapin
WO2005079851A2 (en) 2004-02-18 2005-09-01 Sepracor, Inc. Dopamine-agonist combination therapy with sedatives for improving sleep quality
MXPA06012777A (es) 2004-05-06 2007-02-14 Cydex Inc Formulaciones de sabor enmascarado que contienen sertralina y eter sulfoalquilico-ciclodextrina.
WO2006007448A2 (en) 2004-06-17 2006-01-19 Transform Pharmaceuticals, Inc. Pharmaceutical co-crystal compositions and related methods of use
WO2006096439A2 (en) 2005-03-04 2006-09-14 Boehringer Ingelheim International Gmbh Pharmaceutical compositions for the treatment and/or prevention of schizophrenia and related diseases
CA2505808A1 (en) * 2005-05-02 2006-11-02 Julie Danielle Globus Niacin used as oral supplementation for the treatment of psychosis and/or schizophrenia in humans
WO2006129160A2 (en) 2005-06-01 2006-12-07 Aurobindo Pharma Limited Stable aqueous oral solution of risperidone
US20110045065A1 (en) 2005-07-11 2011-02-24 Ashok Vasantray Vyas Substance having antioxidant, geroprotective and anti-ischemic activity and method for the preparation thereof
US7811604B1 (en) 2005-11-14 2010-10-12 Barr Laboratories, Inc. Non-effervescent, orally disintegrating solid pharmaceutical dosage forms comprising clozapine and methods of making and using the same
GB0603181D0 (en) 2006-02-17 2006-03-29 Merck Sharp & Dohme Treatment of neurodegenerative and psychiatric diseases
US20080045512A1 (en) 2006-08-09 2008-02-21 Pfizer Inc. Benzoate salt of 4-(5-methyl-oxazolo[4,5-b]-pyridin-2-yl)-1,4-diazabicyclo[3.2.2]nonane
WO2008034087A2 (en) 2006-09-15 2008-03-20 Xenoport, Inc. Treating schizophrenia with combinations of levodopa and an antipsychotic agent
US8071143B2 (en) * 2008-04-02 2011-12-06 Brandeis University Methods for the treatment or prevention of diabetes mellitus and other metabolic imbalances
US8541435B2 (en) * 2008-07-11 2013-09-24 Uday Saxena Niacin compositions for reduction of amyloid beta peptide 42 (abeta 42) production and for treatment of Alzheimer's disease (AD)
US20130338199A1 (en) * 2008-07-11 2013-12-19 Uday Saxena Novel Niacin Compositions for Reduction of Amyloid Beta Peptide 42 (AB42) Production and for Treatment of Alzheimer's Disease
GB0813709D0 (en) * 2008-07-26 2008-09-03 Univ Dundee Method and product
JP2010106001A (ja) * 2008-10-31 2010-05-13 Theravalues Corp Ｐｐａｒ活性化剤
CN102292094B (zh) 2009-01-20 2013-08-14 洛杉矶生物医学研究所在哈伯-加州大学洛杉矶分校医疗中心 增强神经药方疗效的山梨酸与苯甲酸及其衍生物
EP3597628A1 (en) * 2010-07-23 2020-01-22 Grünenthal GmbH Salts or co-crystals of 3-(3-dimethylamino-1-ethyl-2-methyl-propyl)-phenol
CA2831086A1 (en) * 2011-03-24 2012-09-27 University Of South Florida Lithium compositions
TWI542596B (zh) * 2011-05-09 2016-07-21 健生藥品公司 （２ｓ,３ｒ,４ｒ,５ｓ,６ｒ）－２－（３－（（５－（４－氟苯基）噻吩－２－基）甲基）－４－甲基苯基）－６－（羥甲基）四氫－２ｈ－哌喃－３,４,５－三醇之ｌ－脯胺酸及檸檬酸共晶體
US9120766B2 (en) * 2011-10-21 2015-09-01 Amri Ssci, Llc Methods of making cocrystals
HUE057879T2 (hu) 2013-04-19 2022-06-28 Univ South Florida Szerves anion lítiumos kokristályos vegyületek és összetételek
WO2014178040A1 (en) 2013-04-29 2014-11-06 Mapi Pharma Ltd. Co-crystals of dapagliflozin
EP3079675B1 (en) * 2013-12-13 2020-02-12 CONARIS research institute AG A pharmaceutical composition containing nicotinic acid and/or nicotinamide for use in beneficially influencing blood lipid levels by modifying the intestinal microbiota
KR20160029837A (ko) * 2014-03-24 2016-03-15 가오슝 창 궁 메모리얼 하스피털 치매 또는 경도 인지 장애의 예방 또는 치료용 조성물의 제조에 사용하는 벤조산염의 용도
CN103992320A (zh) * 2014-05-26 2014-08-20 南京工业大学 一种混悬结晶制备药物共晶的方法
WO2016081365A1 (en) * 2014-11-19 2016-05-26 Rush University Medical Center Compositions and methods for treating lysosomal disorders
RU2582962C1 (ru) * 2014-12-23 2016-04-27 Ольга Алексеевна Громова Средство для профилактики и лечения нейродегенеративной патологии и сосудистой деменции (варианты)
ES2936094T3 (es) 2016-06-13 2023-03-14 Syneurx Int Taiwan Corp Cocristales de benzoato de sodio y usos de los mismos

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Adam J. Smith et al., Improving lithium therapeutics by crystal engineering of novel ionic cocrystals, Mol Pharm, 2013, 10, 4728-4738. (2013.11.05.)
Christian Butterhof et al., Influence of cation size on the co-crystallisation of benzoic acid with different benzoates, Z Anorg Allg Chem, 2013, 639(2), 308-311. (2013.01.04.)

Also Published As

Publication number Publication date
CA3027300A1 (en) 2017-12-21
CN109563024B (zh) 2023-06-06
US20190177261A1 (en) 2019-06-13
RU2022101542A (ru) 2022-02-03
TWI736635B (zh) 2021-08-21
EP3468946A1 (en) 2019-04-17
EP3468946A4 (en) 2020-02-12
TW201811321A (zh) 2018-04-01
US10815184B2 (en) 2020-10-27
JP6958923B2 (ja) 2021-11-02
US20210107856A1 (en) 2021-04-15
JP2019518757A (ja) 2019-07-04
KR20190017939A (ko) 2019-02-20
KR20210142769A (ko) 2021-11-25
KR102338171B1 (ko) 2021-12-09
IL263486B (en) 2021-08-31
MX2018015463A (es) 2019-05-27
IL263486A (en) 2019-01-31
CA3027300C (en) 2023-08-08
RU2018146423A3 (https=) 2020-10-06
RU2018146423A (ru) 2020-07-14
RU2765625C2 (ru) 2022-02-01
US11739046B2 (en) 2023-08-29
CN109563024A (zh) 2019-04-02
WO2017215592A1 (en) 2017-12-21

Similar Documents

Publication Publication Date Title
JP7723991B2 (ja) 置換グリシン化合物の共結晶およびそれの使用
US11731928B2 (en) Co-crystals of sodium benzoate and uses thereof
US11739046B2 (en) Co-crystals of lithium benzoate and uses thereof
WO2014193837A1 (en) Synthesis of galanal compounds and analogues thereof
RU2771810C2 (ru) Сокристаллы бензоата натрия и их применение
US8658677B2 (en) Pyridyl-2-methylamino compounds, compositions and uses thereof
HK40017282A (en) Co-crystals of substituted glycine compounds and uses thereof
HK40017282B (en) Co-crystals of substituted glycine compounds and uses thereof

Legal Events

Date Code Title Description
A107 Divisional application of patent
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20211115

Application number text: 1020197000865

Filing date: 20190110

AMND Amendment
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20211125

Comment text: Request for Examination of Application

PG1501 Laying open of application
E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20220103

Patent event code: PE09021S01D

AMND Amendment
E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20220801

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20220103

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

AMND Amendment
PX0901 Re-examination

Patent event code: PX09011S01I

Patent event date: 20220801

Comment text: Decision to Refuse Application

Patent event code: PX09012R01I

Patent event date: 20220628

Comment text: Amendment to Specification, etc.

Patent event code: PX09012R01I

Patent event date: 20211125

Comment text: Amendment to Specification, etc.

PX0701 Decision of registration after re-examination

Patent event date: 20221108

Comment text: Decision to Grant Registration

Patent event code: PX07013S01D

Patent event date: 20221028

Comment text: Amendment to Specification, etc.

Patent event code: PX07012R01I

Patent event date: 20220801

Comment text: Decision to Refuse Application

Patent event code: PX07011S01I

Patent event date: 20220628

Comment text: Amendment to Specification, etc.

Patent event code: PX07012R01I

Patent event date: 20211125

Comment text: Amendment to Specification, etc.

Patent event code: PX07012R01I

X701 Decision to grant (after re-examination)
GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20230111

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20230111

End annual number: 3

Start annual number: 1

PG1601 Publication of registration